Eight-week follow-up data show separation of clinical efficacy scores between treatment group and placebo group through the duration of study
Total and pathogenic IgG reduction correlates with disease score [...]
Dr. Ulrich Dauer to team up with Chief Development Officer, Dr. Inge Lues, effective May 1, 2018; Dr. Konrad Glund and Dr. Hendrik Liebers to continue in advisory roles
HALLE (SAALE), Germany, 23 April 2018 - [...]
Breda, the Netherlands/Ghent, Belgium, April 12, 2018 - argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment o [...]
Zealand has entered a collaboration agreement with Roche Diabetes Care to use its Accu-Chek® Combo pump system in the Phase 3 trials with dasiglucagon for treatment of congenital hyperinsulinism (CHI).
The [...]
Breda, the Netherlands / Ghent, Belgium, April 9, 2018 - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatmen [...]
Breda, the Netherlands / Ghent, Belgium, March 26, 2018 - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatme [...]
UTRECHT, The Netherlands, March 20, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), and the Vall d’He [...]
Merus’ First U.S. Patent Covering MCLA-117 and Merus’ Spleen to Screen® Technology for Efficient Generation of Biclonics® Candidates
UTRECHT, The Netherlands, March 13, 2018 (GLOBE NEWSWIRE) -- Merus N. [...]
Eight-week follow-up data show separation of clinical efficacy scores between treatment group and placebo group through the duration of study
Total and pathogenic IgG reduction correlates with disease score [...]
Dr. Ulrich Dauer to team up with Chief Development Officer, Dr. Inge Lues, effective May 1, 2018; Dr. Konrad Glund and Dr. Hendrik Liebers to continue in advisory roles
HALLE (SAALE), Germany, 23 April 2018 - [...]
Breda, the Netherlands/Ghent, Belgium, April 12, 2018 - argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment o [...]
Zealand has entered a collaboration agreement with Roche Diabetes Care to use its Accu-Chek® Combo pump system in the Phase 3 trials with dasiglucagon for treatment of congenital hyperinsulinism (CHI).
The [...]
Breda, the Netherlands / Ghent, Belgium, April 9, 2018 - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatmen [...]
Breda, the Netherlands / Ghent, Belgium, March 26, 2018 - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatme [...]
UTRECHT, The Netherlands, March 20, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), and the Vall d’He [...]
Merus’ First U.S. Patent Covering MCLA-117 and Merus’ Spleen to Screen® Technology for Efficient Generation of Biclonics® Candidates
UTRECHT, The Netherlands, March 13, 2018 (GLOBE NEWSWIRE) -- Merus N. [...]
Follow us
